Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

NCT01767896 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1020

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: ASP7374
BIOLOGICAL: approved egg-derived TIV

Sponsor

UMN Pharma Inc.